Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

The safety and effectiveness of a long-acting transdermal fentanyl solution compared with oxymorphone for the control of postoperative pain in dogs: a randomized, multicentered clinical study.

Martinez SA, Wilson MG, Linton DD, Newbound GC, Freise KJ, Lin TL, Clark TP.

J Vet Pharmacol Ther. 2014 Aug;37(4):394-405. doi: 10.1111/jvp.12096. Epub 2013 Dec 18.

2.

Population pharmacokinetics of transdermal fentanyl solution following a single dose administered prior to soft tissue and orthopedic surgery in dogs.

Freise KJ, Linton DD, Newbound GC, Tudan C, Clark TP.

J Vet Pharmacol Ther. 2012 Aug;35 Suppl 2:65-72. doi: 10.1111/j.1365-2885.2012.01407.x.

PMID:
22731777
3.

The effectiveness of a long-acting transdermal fentanyl solution compared to buprenorphine for the control of postoperative pain in dogs in a randomized, multicentered clinical study.

Linton DD, Wilson MG, Newbound GC, Freise KJ, Clark TP.

J Vet Pharmacol Ther. 2012 Aug;35 Suppl 2:53-64. doi: 10.1111/j.1365-2885.2012.01408.x.

PMID:
22731776
4.

Naloxone reversal of an overdose of a novel, long-acting transdermal fentanyl solution in laboratory Beagles.

Freise KJ, Newbound GC, Tudan C, Clark TP.

J Vet Pharmacol Ther. 2012 Aug;35 Suppl 2:45-51. doi: 10.1111/j.1365-2885.2012.01409.x.

PMID:
22731775
5.

The margin of safety of a single application of transdermal fentanyl solution when administered at multiples of the therapeutic dose to laboratory dogs.

Savides MC, Pohland RC, Wilkie DA, Abbott JA, Newbound GC, Freise KJ, Clark TP.

J Vet Pharmacol Ther. 2012 Aug;35 Suppl 2:35-43. doi: 10.1111/j.1365-2885.2012.01410.x.

PMID:
22731774
6.

Pharmacokinetics and the effect of application site on a novel, long-acting transdermal fentanyl solution in healthy laboratory Beagles.

Freise KJ, Newbound GC, Tudan C, Clark TP.

J Vet Pharmacol Ther. 2012 Aug;35 Suppl 2:27-33. doi: 10.1111/j.1365-2885.2012.01411.x.

PMID:
22731773
7.

Pharmacokinetics and dose selection of a novel, long-acting transdermal fentanyl solution in healthy laboratory Beagles.

Freise KJ, Savides MC, Riggs KL, Owens JG, Newbound GC, Clark TP.

J Vet Pharmacol Ther. 2012 Aug;35 Suppl 2:21-6. doi: 10.1111/j.1365-2885.2012.01399.x.

PMID:
22731772
9.

Endoplasmic reticulum and cis-Golgi localization of human T-lymphotropic virus type 1 p12(I): association with calreticulin and calnexin.

Ding W, Albrecht B, Luo R, Zhang W, Stanley JR, Newbound GC, Lairmore MD.

J Virol. 2001 Aug;75(16):7672-82.

10.

Rhesus monkey model for fetal gene transfer: studies with retroviral- based vector systems.

Tarantal AF, O'Rourke JP, Case SS, Newbound GC, Li J, Lee CI, Baskin CR, Kohn DB, Bunnell BA.

Mol Ther. 2001 Feb;3(2):128-38.

11.

Analysis of gene transfer efficiency of retrovirus producer cell transplantation for in situ gene transfer to hematopoietic cells.

Newbound GC, Cooper JR, O'Rourke JP, Baskin CR, Bunnell BA.

Exp Hematol. 2001 Feb;29(2):163-73.

PMID:
11166455
12.

Repression of tax-mediated human t-lymphotropic virus type 1 transcription by inducible cAMP early repressor (ICER) protein in peripheral blood mononuclear cells.

Newbound GC, O'Rourke JP, Collins ND, Andrews JM, DeWille J, Lairmore MD.

J Med Virol. 2000 Oct;62(2):286-92.

PMID:
11002260
13.

CCAAT/enhancer-binding protein delta regulates mammary epithelial cell G0 growth arrest and apoptosis.

O'Rourke JP, Newbound GC, Hutt JA, DeWille J.

J Biol Chem. 1999 Jun 4;274(23):16582-9.

14.

Comparison of HTLV-I basal transcription and expression of CREB/ATF-1/CREM family members in peripheral blood mononuclear cells and Jurkat T cells.

Newbound GC, O'Rourke JP, Collins ND, DeWille J, Lairmore MD.

J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Jan 1;20(1):1-10.

PMID:
9928723
15.

CD2 signalling induces phosphorylation of CREB in primary lymphocytes.

Guyot DJ, Newbound GC, Lairmore MD.

Immunology. 1998 Dec;95(4):544-52.

16.

Quantification of human T-cell lymphotropic virus type 1 proviral load by quantitative competitive polymerase chain reaction.

Albrecht B, Collins ND, Newbound GC, Ratner L, Lairmore MD.

J Virol Methods. 1998 Nov;75(2):123-40.

PMID:
9870588
17.

Selective ablation of human T-cell lymphotropic virus type 1 p12I reduces viral infectivity in vivo.

Collins ND, Newbound GC, Albrecht B, Beard JL, Ratner L, Lairmore MD.

Blood. 1998 Jun 15;91(12):4701-7.

PMID:
9616168
18.
19.

Signaling via the CD2 receptor enhances HTLV-1 replication in T lymphocytes.

Guyot DJ, Newbound GC, Lairmore MD.

Virology. 1997 Jul 21;234(1):123-9.

20.
22.
23.

Human T-cell lymphotropic virus type 1 Tax mediates enhanced transcription in CD4+ T lymphocytes.

Newbound GC, Andrews JM, O'Rourke JP, Brady JN, Lairmore MD.

J Virol. 1996 Apr;70(4):2101-6.

24.

Stimulation of the CD2 receptor pathway induces apoptosis in human T lymphotropic virus type I-infected cell lines.

Guyot DJ, Trask OJ, Andrews JM, Newbound GC, Lairmore MD.

J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Apr 1;11(4):317-25.

PMID:
8601217
25.

Enhanced human T-cell lymphotropic virus type I expression following induction of the cellular stress response.

Andrews JM, Oglesbee MJ, Trevino AV, Guyot DJ, Newbound GC, Lairmore MD.

Virology. 1995 Apr 20;208(2):816-20.

26.

Preliminary analysis of the polypeptides of the salmon leukemia virus (SLV) and evidence for development of a bimodal viremia following SLV infection.

Eaton WD, Folkins B, Kent ML, Dawe S, Newbound GC, Zinkl J.

Vet Microbiol. 1994 Nov;42(2-3):217-27.

PMID:
7533962
27.

Effects of whole blood lysis and fixation on the infectivity of human T-lymphotropic virus type 1 (HTLV-I).

Ericson JG, Trevino AV, Toedter GP, Mathes LE, Newbound GC, Lairmore MD.

Cytometry. 1994 Mar 15;18(1):49-54.

28.

Production of monoclonal antibodies specific for antigens derived from tissue of chinook salmon (Oncorhynchus tshawytscha) affected with plasmacytoid leukemia.

Newbound GC, Markham RJ, Speare DJ, Saksida SM, Despr├ęs BM, Horney BS, Kibenge FS, Sheppard JA, Wright GM, Kent ML.

Am J Vet Res. 1993 Sep;54(9):1426-31.

PMID:
8239128

Supplemental Content

Loading ...
Support Center